PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the...
Japanese Product Now Under Review for Nationwide Marketing Approval PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company...
Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety KarXT Is a Potential...
Strong strategic and clinical progress in 2023, with multiple catalysts expected in 2024 Launching of two new Founded Entities to advance certain...
LYT-200 demonstrates favorable safety profile and anti-tumor activity in combination with anti-PD-1 agent, tislelizumab Three out of four...
Prescription Drug User Fee Act (PDUFA) action date is September 26, 2024 If approved, KarXT would represent the first new pharmacological...
Results demonstrate KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia KarXT...
Orally administered LYT-300 achieved a statistically significant (p=0.0001) reduction in the stress hormone...
Company summarizes third quarter progress across its Wholly Owned Pipeline and Founded Entities PureTech Health plc (Nasdaq: PRTC, LSE: PRTC...
LYT-100 demonstrated ~50% improvement versus pirfenidone in key adverse events at a comparable exposure level, which may lead to better patient...
VE202 is an orally administered, rationally-defined bacterial consortium candidate for the treatment of ulcerative colitis Vedanta’s pipeline...
Founded Entity Karuna Therapeutics submits New Drug Application to U.S. Food and Drug Administration for KarXT for the treatment of schizophrenia...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.